• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy.

作者信息

Li Dalin, Xu Alexander, Mengesha Emebet, Elyanow Rebecca, Gittelman Rachel M, Chapman Heidi, Prostko John C, Frias Edwin C, Stewart James L, Pozdnyakova Valeriya, Debbas Philip, Mujukian Angela, Horizon Arash A, Merin Noah, Joung Sandy, Botwin Gregory J, Sobhani Kimia, Figueiredo Jane C, Cheng Susan, Kaplan Ian M, McGovern Dermot P B, Merchant Akil, Melmed Gil Y, Braun Jonathan

机构信息

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Inflamm Bowel Dis. 2022 Jul 1;28(7):1130-1133. doi: 10.1093/ibd/izac071.

DOI:10.1093/ibd/izac071
PMID:35397000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9047232/
Abstract
摘要

相似文献

1
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy.炎症性肠病中抗TNF治疗增强了对SARS-CoV-2疫苗接种的T细胞反应。
Inflamm Bowel Dis. 2022 Jul 1;28(7):1130-1133. doi: 10.1093/ibd/izac071.
2
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.T 细胞对接受 TNF 抑制剂治疗的患者反复接种 SARS-CoV-2 疫苗和突破性感染的反应：一项前瞻性队列研究。
EBioMedicine. 2024 Oct;108:105317. doi: 10.1016/j.ebiom.2024.105317. Epub 2024 Sep 10.
3
Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.在接受抗TNF或其他治疗的炎症性肠病患者中，接种三剂新冠疫苗后产生强大的新冠病毒抗体和T细胞免疫。
Gut. 2024 Mar 7;73(4):712-714. doi: 10.1136/gutjnl-2022-329136.
4
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.COVID-19 疫苗接种后第三剂后炎症性肠病免疫抑制患者的抗体和 T 细胞反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
5
Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.COVID-19 疫苗接种后，接受抗 TNF 治疗的炎症性肠病患者的细胞介导免疫反应更高。
Inflamm Bowel Dis. 2023 Aug 1;29(8):1202-1209. doi: 10.1093/ibd/izac193.
6
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8 T cell responses.接种 mRNA-1273 的炎症性肠病患者接受 TNF 抑制剂治疗后会产生广泛而强烈的 SARS-CoV-2 特异性 CD8 T 细胞应答。
J Autoimmun. 2024 Apr;144:103175. doi: 10.1016/j.jaut.2024.103175. Epub 2024 Feb 21.
7
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.抗 SARS-CoV-2 疫苗接种和免疫调节治疗的炎症性肠病患者的抗体反应：前瞻性单中心研究。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1506-1512. doi: 10.1093/ibd/izab301.
8
Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.抗肿瘤坏死因子治疗与炎症性肠病患者对 SARS-CoV-2 疫苗的体液免疫应答减弱相关。
Vaccine. 2023 Jun 13;41(26):3862-3871. doi: 10.1016/j.vaccine.2023.05.012. Epub 2023 May 8.
9
Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.肠道炎症中 SARS-CoV-2 免疫的全身和 T 细胞相关反应（STAR SIGN 研究）：生物制剂对 mRNA 疫苗第三剂预防 SARS-CoV-2 效果的影响。
Aliment Pharmacol Ther. 2023 Jan;57(1):103-116. doi: 10.1111/apt.17264. Epub 2022 Oct 28.
10
Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON].炎症性肠病患者对 COVID-19 疫苗的血清学反应降低，而 TNF 抑制剂治疗进一步降低；VARIATION 研究的早期结果 [针对 SARS-COV-2 免疫的 IBD 反应变异性]。
J Crohns Colitis. 2022 Sep 8;16(9):1354-1362. doi: 10.1093/ecco-jcc/jjac029.

引用本文的文献

1
Impaired Long-Term Quantitative Cellular Response to SARS-CoV-2 Vaccine in Thiopurine-Treated IBD Patients.硫嘌呤治疗的炎症性肠病患者对SARS-CoV-2疫苗的长期定量细胞反应受损。
Cells. 2025 Jul 26;14(15):1156. doi: 10.3390/cells14151156.
2
Low booster uptake in cancer patients despite health benefits.尽管有健康益处，但癌症患者的加强针接种率较低。
iScience. 2024 Jul 26;27(9):110596. doi: 10.1016/j.isci.2024.110596. eCollection 2024 Sep 20.
3
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.

本文引用的文献

1
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.抗 TNF-α 治疗的炎症性肠病患者对 COVID-19 mRNA 疫苗的血清学反应较低。
Gastroenterology. 2022 Feb;162(2):454-467. doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.
2
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.肿瘤坏死因子抑制剂与 COVID-19 合并免疫介导的炎症性疾病患者住院或死亡风险的相关性。
JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639.
3
新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
4
Higher and Sustained Cell-Mediated Immune Responses After 3 Doses of mRNA COVID-19 Vaccine in Patients With Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.接受抗肿瘤坏死因子治疗的炎症性肠病患者接种3剂mRNA新冠疫苗后产生更高且持续的细胞介导免疫反应。
Clin Transl Gastroenterol. 2024 Apr 1;15(4):e00688. doi: 10.14309/ctg.0000000000000688.
5
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.炎症性肠病患者接种三剂新冠病毒疫苗（VIP）后针对新冠病毒奥密克戎BA.4/5和野生型病毒的中和抗体反应：一项前瞻性、多中心队列研究
EClinicalMedicine. 2023 Oct 5;64:102249. doi: 10.1016/j.eclinm.2023.102249. eCollection 2023 Oct.
6
Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving -TNF therapy: A systematic review and meta-analysis.新冠病毒疫苗在接受肿瘤坏死因子治疗的炎症性肠病患者中的疗效：一项系统评价和荟萃分析。
Heliyon. 2023 Sep 5;9(9):e19609. doi: 10.1016/j.heliyon.2023.e19609. eCollection 2023 Sep.
7
A Paratope-Enhanced Method to Determine Breadth and Depth TCR Clonal Metrics of the Private Human T-Cell Vaccine Response after SARS-CoV-2 Vaccination.一种增强表位的方法，用于确定 SARS-CoV-2 疫苗接种后私人人类 T 细胞疫苗反应的广度和深度 TCR 克隆指标。
Int J Mol Sci. 2023 Sep 18;24(18):14223. doi: 10.3390/ijms241814223.
8
Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.COVID-19 对有和无预先存在的消化系统疾病的个体的影响，特别关注老年患者。
World J Gastroenterol. 2023 Jul 14;29(26):4099-4119. doi: 10.3748/wjg.v29.i26.4099.
9
COVID-19 vaccination in adults with inflammatory bowel disease.炎症性肠病成年患者的新冠病毒疫苗接种
Therap Adv Gastroenterol. 2023 May 22;16:17562848231173130. doi: 10.1177/17562848231173130. eCollection 2023.
10
Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.抗肿瘤坏死因子治疗与炎症性肠病患者对 SARS-CoV-2 疫苗的体液免疫应答减弱相关。
Vaccine. 2023 Jun 13;41(26):3862-3871. doi: 10.1016/j.vaccine.2023.05.012. Epub 2023 May 8.
Antibody Responses After SARS-CoV-2 mRNA Vaccination in Adults With Inflammatory Bowel Disease.
炎症性肠病成年患者接种SARS-CoV-2 mRNA疫苗后的抗体反应
Ann Intern Med. 2021 Dec;174(12):1768-1770. doi: 10.7326/M21-2483. Epub 2021 Oct 12.
4
Rapid and stable mobilization of CD8 T cells by SARS-CoV-2 mRNA vaccine.SARS-CoV-2 mRNA 疫苗可快速稳定地动员 CD8 T 细胞。
Nature. 2021 Sep;597(7875):268-273. doi: 10.1038/s41586-021-03841-4. Epub 2021 Jul 28.
5
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.甲氨蝶呤和靶向免疫抑制对COVID-19疫苗BNT162b2体液和细胞免疫反应的影响：一项队列研究。
Lancet Rheumatol. 2021 Sep;3(9):e627-e637. doi: 10.1016/S2665-9913(21)00212-5. Epub 2021 Jul 8.
6
Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine.在一组接种BNT162b2 mRNA疫苗的意大利医护人员中体液和刺突特异性T细胞反应的协同诱导
Microorganisms. 2021 Jun 16;9(6):1315. doi: 10.3390/microorganisms9061315.
7
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.与年龄相关的对 SARS-CoV-2 疫苗 BNT162b2 的免疫反应异质性。
Nature. 2021 Aug;596(7872):417-422. doi: 10.1038/s41586-021-03739-1. Epub 2021 Jun 30.
8
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.Ad26.COV2.S 疫苗对人类 SARS-CoV-2 变异株的免疫原性。
Nature. 2021 Aug;596(7871):268-272. doi: 10.1038/s41586-021-03681-2. Epub 2021 Jun 9.
9
Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.炎症性肠病患者接种 SARS-CoV-2 mRNA 疫苗后的不良反应。
Am J Gastroenterol. 2021 Aug 1;116(8):1746-1751. doi: 10.14309/ajg.0000000000001342.
10
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.英夫利昔单抗与 IBD 患者对 BNT162b2 和 ChAdOx1 nCoV-19 SARS-CoV-2 疫苗的免疫原性降低有关。
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.